Integra LifeSciences Holdings Corporation

Informe acción NasdaqGS:IART

Capitalización de mercado: US$1.8b

Integra LifeSciences Holdings Dirección

Dirección controles de criterios 4/4

El CEO de Integra LifeSciences Holdings es Jan De Witte , nombrado en Dec 2021, tiene una permanencia de 2.92 años. compensación anual total es $6.39M, compuesta por 13.7% salario y 86.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.031% de las acciones de la empresa, por valor de $549.82K. La antigüedad media del equipo directivo y de la junta directiva es de 3.6 años y 11.5 años, respectivamente.

Información clave

Jan De Witte

Chief Executive Officer (CEO)

US$6.4m

Compensación total

Porcentaje del salario del CEO13.7%
Permanencia del CEO2.9yrs
Participación del CEO0.03%
Permanencia media de la dirección3.6yrs
Promedio de permanencia en la Junta Directiva11.5yrs

Actualizaciones recientes de la dirección

Recent updates

There's No Escaping Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Muted Revenues Despite A 42% Share Price Rise

Nov 05
There's No Escaping Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Muted Revenues Despite A 42% Share Price Rise

Is Now The Time To Look At Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Oct 24
Is Now The Time To Look At Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Why Investors Shouldn't Be Surprised By Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Low P/S

Sep 08
Why Investors Shouldn't Be Surprised By Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Low P/S

Is Integra LifeSciences Holdings (NASDAQ:IART) A Risky Investment?

Aug 21
Is Integra LifeSciences Holdings (NASDAQ:IART) A Risky Investment?

At US$29.14, Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Worth Looking At Closely?

Jul 01
At US$29.14, Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Worth Looking At Closely?

Integra LifeSciences Still Underperforming As Manufacturing Issues Linger

Jun 21

Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Intrinsic Value Is Potentially 40% Above Its Share Price

May 28
Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Intrinsic Value Is Potentially 40% Above Its Share Price

Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Stalled

Feb 27
Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Stalled

We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Feb 11
We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Jan 14
Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Price In Tune With Earnings

Dec 31
Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Price In Tune With Earnings

Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 46% Discount?

Dec 03
Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 46% Discount?

Does Integra LifeSciences Holdings (NASDAQ:IART) Have A Healthy Balance Sheet?

Nov 06
Does Integra LifeSciences Holdings (NASDAQ:IART) Have A Healthy Balance Sheet?

Integra LifeSciences Holdings (NASDAQ:IART) Hasn't Managed To Accelerate Its Returns

Oct 24
Integra LifeSciences Holdings (NASDAQ:IART) Hasn't Managed To Accelerate Its Returns

Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Sep 22
Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 38% Discount?

Aug 15
Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 38% Discount?

Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Hit The Brakes

Jul 03
Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Hit The Brakes

Is There Now An Opportunity In Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Jun 19
Is There Now An Opportunity In Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Estimating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

May 05
Estimating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well

Apr 07
These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well

Integra LifeSciences Holdings (NASDAQ:IART) Is Experiencing Growth In Returns On Capital

Mar 26
Integra LifeSciences Holdings (NASDAQ:IART) Is Experiencing Growth In Returns On Capital

At US$52.61, Is It Time To Put Integra LifeSciences Holdings Corporation (NASDAQ:IART) On Your Watch List?

Mar 14
At US$52.61, Is It Time To Put Integra LifeSciences Holdings Corporation (NASDAQ:IART) On Your Watch List?

Does Integra LifeSciences Holdings (NASDAQ:IART) Deserve A Spot On Your Watchlist?

Feb 27
Does Integra LifeSciences Holdings (NASDAQ:IART) Deserve A Spot On Your Watchlist?

Calculating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Feb 02
Calculating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Jan 05
We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Here's What To Make Of Integra LifeSciences Holdings' (NASDAQ:IART) Decelerating Rates Of Return

Dec 21
Here's What To Make Of Integra LifeSciences Holdings' (NASDAQ:IART) Decelerating Rates Of Return

When Should You Buy Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Dec 08
When Should You Buy Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jan De Witte en comparación con los beneficios de Integra LifeSciences Holdings?
FechaCompensación totalSalarioIngresos de la empresa
Sep 30 2024n/an/a

-US$7m

Jun 30 2024n/an/a

US$24m

Mar 31 2024n/an/a

US$40m

Dec 31 2023US$6mUS$875k

US$68m

Sep 30 2023n/an/a

US$101m

Jun 30 2023n/an/a

US$131m

Mar 31 2023n/an/a

US$172m

Dec 31 2022US$9mUS$850k

US$181m

Sep 30 2022n/an/a

US$173m

Jun 30 2022n/an/a

US$166m

Mar 31 2022n/an/a

US$157m

Dec 31 2021US$899kUS$59k

US$169m

Compensación vs. Mercado: La compensación total ($USD6.39M) de Jan está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD5.43M).

Compensación vs. Ingresos: La compensación de Jan ha sido consistente con los resultados de la empresa en el último año.


CEO

Jan De Witte (60 yo)

2.9yrs

Permanencia

US$6,388,756

Compensación

Mr. Jan De Witte has been President, Chief Executive Officer & Director of Integra LifeSciences Holdings Corporation since December 1, 2021. He had been the Chief Executive Officer at Barco NV since Septem...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Stuart Essig
Executive Chairman26.9yrsUS$422.52k2.27%
$ 40.3m
Jan De Witte
President2.9yrsUS$6.39m0.031%
$ 549.8k
Lea Knight
Executive VP & CFO1.4yrsUS$1.67m0.054%
$ 964.6k
Jeffrey Mosebrook
Senior VP of Finance & Principal Accounting Officer7.1yrsUS$1.25m0.047%
$ 830.1k
Eric Schwartz
Executive VP6yrsUS$1.62m0.082%
$ 1.5m
Robert Davis
Executive VP & President of Tissue Technologies11.9yrsUS$1.42m0.084%
$ 1.5m
Michael McBreen
Executive VP & President of Codman Specialty Surgical4.5yrsUS$2.83m0.075%
$ 1.3m
Stephen Leonard
Corporate VP of Global Operations & Supply Chain4.3yrssin datossin datos
Laurene Isip
Vice President of Global Corporate Communications & Public Relationsno datasin datossin datos
Ruth Fleming
Vice President of Global Marketingno datasin datossin datos
Chantal Veillon-Berteloot
Executive VP & Chief Human Resources Officer1.8yrssin datos0.032%
$ 560.6k
Mark Jesser
Corporate VP & Chief Digital Officer2.8yrssin datossin datos

3.6yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de IART se considera experimentado (3.6 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Stuart Essig
Executive Chairman26.9yrsUS$422.52k2.27%
$ 40.3m
Jan De Witte
President2.9yrsUS$6.39m0.031%
$ 549.8k
Raymond Murphy
Independent Director15.6yrsUS$297.54k0.11%
$ 1.9m
Christian Schade
Independent Director18.8yrsUS$293.28k0.082%
$ 1.5m
Barbara Hill
Independent Presiding Director11.5yrsUS$342.54k0.18%
$ 3.1m
Keith N. Bradley
Independent Director32.8yrsUS$306.31k0.091%
$ 1.6m
Jeffrey Graves
Independent Directorless than a yearUS$90.68k0.016%
$ 287.3k
Shaundra Clay
Independent Director3.6yrsUS$260.04k0.028%
$ 504.2k
Renee Lo
Independent Director2.3yrsUS$297.54k0.021%
$ 371.5k

11.5yrs

Permanencia media

63yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de IART son experimentados ( 11.5 años antigüedad media).